MXPA05008171A - Nueva forma cristalina de la 2-(3, 5-bis- trifluormetil -fenil) -n-[6- (1, 1-dioxo -1 lambda 6- tiomorfolin -4-il)- 4-(4-fluor -2-metil -fenil)- piridin-3 -il]-n -metil- isobutiramida. - Google Patents
Nueva forma cristalina de la 2-(3, 5-bis- trifluormetil -fenil) -n-[6- (1, 1-dioxo -1 lambda 6- tiomorfolin -4-il)- 4-(4-fluor -2-metil -fenil)- piridin-3 -il]-n -metil- isobutiramida.Info
- Publication number
- MXPA05008171A MXPA05008171A MXPA05008171A MXPA05008171A MXPA05008171A MX PA05008171 A MXPA05008171 A MX PA05008171A MX PA05008171 A MXPA05008171 A MX PA05008171A MX PA05008171 A MXPA05008171 A MX PA05008171A MX PA05008171 A MXPA05008171 A MX PA05008171A
- Authority
- MX
- Mexico
- Prior art keywords
- phenyl
- methyl
- 1lambda
- thiomorpholin
- dioxo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Detergent Compositions (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invencion se refiere a una nueva modificacion cristalina de la 2-(3, 5-bis- trifluormetil- fenil)-N- [6-(1, 1-dioxo-1?6 -tiomorfolin-4 -il)-4 -(4-fluor-2 -metil -fenil)- piridin-3 -il] -N-metil -isobutiramida, caracterizada por el siguiente modelo de difraccion por rayos X, obtenido con una radiacion Cuk? a 2? (2teta)= 4.5, 6.4, 7.5, 7.7, 8.0, 8.2, 10.0, 10.2, 10.9, 11.1, 12.9, 13.4, 14.0, 14.5, 15.1, 15.6, 16.2, 16.5, 17.3, 17.5, 18.0, 18.9, 19.3, 19.5, 19.9, 20.1, 20.6, 21.0, 21.4, 22.7, 23.1, y 23.6 y un espectro de infrarrojos con bandas agudas a 2925, 2854, 1637, 1604, 1484, 1395, 1375, 1285, 1230, 1172, 1125, 1082, 999, 943, 893, 868, 860, 782, 705, 684 cm-1, y en donde el punto de fusion extrapolado (DSC) es de 137.2°C.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03002134 | 2003-01-31 | ||
PCT/EP2004/000547 WO2004067007A1 (en) | 2003-01-31 | 2004-01-23 | NEW CRYSTALLINE MODIFICATION OF 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N-[6-(1,1-DIOXO-1λ6-THIOMORPHOLIN-4-YL)-4(4-FLUORO-2-METHYL-PHENYL)-PYRIDIN-3-YL]-N-METHYL-ISOBUTYRAMIDE |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05008171A true MXPA05008171A (es) | 2005-10-05 |
Family
ID=32798734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05008171A MXPA05008171A (es) | 2003-01-31 | 2004-01-23 | Nueva forma cristalina de la 2-(3, 5-bis- trifluormetil -fenil) -n-[6- (1, 1-dioxo -1 lambda 6- tiomorfolin -4-il)- 4-(4-fluor -2-metil -fenil)- piridin-3 -il]-n -metil- isobutiramida. |
Country Status (28)
Country | Link |
---|---|
US (1) | US7160881B2 (es) |
EP (1) | EP1592428B1 (es) |
JP (1) | JP5026702B2 (es) |
KR (1) | KR100700421B1 (es) |
CN (1) | CN100562320C (es) |
AR (1) | AR042980A1 (es) |
AT (1) | ATE366576T1 (es) |
AU (1) | AU2004208483B8 (es) |
BR (1) | BRPI0406702A (es) |
CA (1) | CA2514037C (es) |
CL (1) | CL2004000150A1 (es) |
CO (1) | CO5580750A2 (es) |
DE (1) | DE602004007486T2 (es) |
ES (1) | ES2290666T3 (es) |
GT (1) | GT200400009A (es) |
HR (1) | HRP20050664A2 (es) |
IL (1) | IL169600A (es) |
MX (1) | MXPA05008171A (es) |
MY (1) | MY135785A (es) |
NO (1) | NO20053431L (es) |
NZ (1) | NZ541243A (es) |
PA (1) | PA8594601A1 (es) |
PE (1) | PE20040944A1 (es) |
PL (1) | PL378404A1 (es) |
RU (1) | RU2330022C2 (es) |
TW (1) | TWI293294B (es) |
WO (1) | WO2004067007A1 (es) |
ZA (1) | ZA200505567B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE500224T1 (de) | 2004-07-06 | 2011-03-15 | Hoffmann La Roche | Herstellungsverfahren für carboxamid-pyridin- derivate als zwischenprodukte bei der synthese von nk-1-rezeptor-antagonisten |
KR20070094666A (ko) | 2005-02-25 | 2007-09-20 | 에프. 호프만-라 로슈 아게 | 약제 물질 분산성이 향상된 정제 |
DK2470545T3 (da) * | 2009-08-27 | 2014-01-13 | Nerre Therapeutics Ltd | Anhydrate former af et pyridinderivat |
CN103755592A (zh) * | 2013-12-30 | 2014-04-30 | 镇江圣安医药有限公司 | (2z)-氰基-3-羟基-n-[4-(三氟甲基)苯基]-2-丁烯酰胺的衍生物及其应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
EP1462450B1 (en) | 1993-12-29 | 2007-06-13 | MERCK SHARP & DOHME LTD. | Substituted morpholine derivatives and their use as therapeutic agents |
TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
US5972938A (en) * | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
DK1035115T3 (da) | 1999-02-24 | 2005-01-24 | Hoffmann La Roche | 4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister |
DE60210760T2 (de) * | 2001-04-23 | 2006-11-23 | F. Hoffmann-La Roche Ag | Verwendung von nk-1-rezeptorantagonisten gegen benigne prostatahyperplasie |
US6849624B2 (en) * | 2001-07-31 | 2005-02-01 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted amides |
-
2004
- 2004-01-23 CN CN200480003306.7A patent/CN100562320C/zh not_active Expired - Fee Related
- 2004-01-23 JP JP2005518353A patent/JP5026702B2/ja not_active Expired - Fee Related
- 2004-01-23 AT AT04704575T patent/ATE366576T1/de active
- 2004-01-23 CA CA2514037A patent/CA2514037C/en not_active Expired - Fee Related
- 2004-01-23 WO PCT/EP2004/000547 patent/WO2004067007A1/en active IP Right Grant
- 2004-01-23 KR KR1020057014025A patent/KR100700421B1/ko not_active IP Right Cessation
- 2004-01-23 DE DE602004007486T patent/DE602004007486T2/de not_active Expired - Lifetime
- 2004-01-23 NZ NZ541243A patent/NZ541243A/en unknown
- 2004-01-23 ES ES04704575T patent/ES2290666T3/es not_active Expired - Lifetime
- 2004-01-23 PL PL378404A patent/PL378404A1/pl unknown
- 2004-01-23 BR BR0406702-9A patent/BRPI0406702A/pt not_active Application Discontinuation
- 2004-01-23 MX MXPA05008171A patent/MXPA05008171A/es active IP Right Grant
- 2004-01-23 RU RU2005127216/04A patent/RU2330022C2/ru not_active IP Right Cessation
- 2004-01-23 EP EP04704575A patent/EP1592428B1/en not_active Expired - Lifetime
- 2004-01-23 AU AU2004208483A patent/AU2004208483B8/en not_active Ceased
- 2004-01-27 TW TW093101746A patent/TWI293294B/zh active
- 2004-01-27 US US10/766,122 patent/US7160881B2/en not_active Expired - Fee Related
- 2004-01-28 PA PA20048594601A patent/PA8594601A1/es unknown
- 2004-01-28 PE PE2004000110A patent/PE20040944A1/es not_active Application Discontinuation
- 2004-01-29 GT GT200400009A patent/GT200400009A/es unknown
- 2004-01-30 AR ARP040100284A patent/AR042980A1/es unknown
- 2004-01-30 MY MYPI20040288A patent/MY135785A/en unknown
- 2004-01-30 CL CL200400150A patent/CL2004000150A1/es unknown
-
2005
- 2005-07-07 IL IL169600A patent/IL169600A/en unknown
- 2005-07-11 ZA ZA200505567A patent/ZA200505567B/en unknown
- 2005-07-14 NO NO20053431A patent/NO20053431L/no not_active Application Discontinuation
- 2005-07-18 CO CO05070753A patent/CO5580750A2/es not_active Application Discontinuation
- 2005-07-21 HR HR20050664A patent/HRP20050664A2/xx not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001056990A3 (en) | Pyridine derivates as potentiators of glutamate receptors | |
PL372944A1 (en) | 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators | |
WO2003028728A8 (en) | 4-(4-substituted piperazinyl-1yl)-butylcarboxamides as d3 dopamine subtype selective ligands | |
AU1982600A (en) | Novel herbicides | |
RS20050621A (en) | Novel crystalline modification of the anhydrates of boscalid | |
WO2004013131A3 (de) | 4-trifluormethylpyrazolyl substituierte pyridine und pyrimidine | |
MY110142A (en) | Thiazolidinedione derivatives, their production and use | |
MXPA05008171A (es) | Nueva forma cristalina de la 2-(3, 5-bis- trifluormetil -fenil) -n-[6- (1, 1-dioxo -1 lambda 6- tiomorfolin -4-il)- 4-(4-fluor -2-metil -fenil)- piridin-3 -il]-n -metil- isobutiramida. | |
MXPA04007391A (es) | Heterociclos triciclicos fusionados utiles para el tratamiento de padecimientos hiper-proliferantes. | |
HU9700886D0 (en) | New intermediates and process for producing them | |
WO2002060874A8 (en) | Potassium channel inhibitors | |
AU2003303098A1 (en) | Process for the preparation of 2-aminomethylpyridine derivative | |
MXPA03012073A (es) | Amidoderivados heterociclicos. | |
L'abbé et al. | Reactions of a 2 H-azirine with electron-rich olefins; synthesis of dimethyl pyrrole-2, 3-dicarboxylates | |
EP1065202A4 (en) | 6- (ALPHA-FLUOROALKYL) -4-PYRIMIDONES AND THEIR PRODUCTION PROCESS | |
NO964386L (no) | Nye krystallformer av 1-[5-metansulfonamidoindolyl-2-karbonylÅ-4-[3-(1-metyletylamino)-2-pyridinylÅpiperazin | |
AU5925498A (en) | Processes for producing 3-cyanopyridine from 2-methyl-1,5-pentanediamine | |
WO2002086099A3 (de) | Exopolysaccharidproduktion | |
AU2003248059A1 (en) | NOVEL Alpha-KETOAMIDE DERIVATIVE AND USE THEREOF | |
Berthold et al. | The Variable Period of RY Canis Minoris BAV Mitteilungen Nr. 127 | |
L'abbe et al. | Reactions of a 2H-Azirine with Electron-rich Olefins; Synthesis of D i met h y I Py r r o I e-2, 3-di ca r boxy I at es | |
WO2002012459A3 (de) | Verfahren zur verbesserten herstellung von cyanophycin und dessen folgeprodukte | |
AU6911101A (en) | Method for producing 4-bromine-aniline derivatives | |
Yi et al. | A Fuzzy Min-Max Neural Network (FMMNN) Based Gait Phase Classification Method using Electromyography (EMG) Signal | |
AU3661300A (en) | Novel method for the production of etoposide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |